Sarclisa (isatuximab) combination provides unprecedented median progression-free survival
The median progression free survival, increased from 19.2 months to 35.7 months when Sarclisa was added to carfilzomib and dexamethasone
The median progression free survival, increased from 19.2 months to 35.7 months when Sarclisa was added to carfilzomib and dexamethasone
Olumiant is the first and only JAK inhibitor USFDA-approved for the treatment of Covid-19
Nirsevimab is the first investigational immunization designed to protect all infants across the RSV season with a single dose
There is a need for the Ministry of Health to put it on the priority list and address the issues, which are numerous
If granted, Nuvaxovid would be the first protein-based Covid-19 vaccine option for adolescents in Australia and New Zealand
This newly designed small-format detector is made up of caesium iodide technology and is extremely high in resolution, capable of capturing the fine detail of smaller anatomical structures present in paediatric patients
The workshop was organized by the Department of Urology as a first step to enabling government medical colleges in Rajasthan to offer the latest surgical technology
CIVCO RT will also display its recent innovations focusing on improving patient comfort and outcomes
Submission to regulators globally is based on phase 2/3 studies of mRNA-1273 in young children
This action makes Veklury the first approved Covid-19 treatment for children less than 12 years of age
Subscribe To Our Newsletter & Stay Updated